But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

The global race for weight loss solutions has firmly arrived in India—bringing with it hope, hype, and a host of unanswered ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Protein is a cornerstone nutrient for maintaining overall health, but its significance becomes especially prominent for those ...

All of these weight loss medications fall under the pharmaceutical umbrella of Glucagon-like Peptide 1 (GLP-1) receptor ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it ...

Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...